This is a StreetInsider.com Premium Only Page

Replimune (REPL) –

Apr 10, 2024 12:59 PM Form SC 13G/A Replimune Group, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Apr 10, 2024 09:49 AM Form SC 13G/A Replimune Group, Inc. Filed by: STATE STREET CORP

Apr 7, 2024 05:00 PM Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Asso

Apr 4, 2024 08:00 AM Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 3, 2024 08:05 PM Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Peeples-Dyer Veleka

Apr 3, 2024 08:04 PM Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Patel Sushil

Apr 3, 2024 08:03 PM Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Xynos Konstantinos

Apr 3, 2024 08:03 PM Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Pucci Paolo

Apr 3, 2024 08:02 PM Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Hill Emily Luisa

Apr 3, 2024 08:02 PM Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Dhingra Kapil

Apr 3, 2024 08:01 PM Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Levitsky Hyam

Apr 3, 2024 08:01 PM Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Sarchi Christopher

Apr 3, 2024 08:01 PM Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Oliger Christy J.

Apr 3, 2024 08:01 PM Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Schwendenman Andrew

Apr 3, 2024 08:01 PM Form 4 Replimune Group, Inc. For: Apr 01 Filed by: SLATTERY JOSEPH P

Apr 3, 2024 08:01 PM Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Weinand Dieter

Mar 26, 2024 07:34 AM Form 8-K Replimune Group, Inc. For: Mar 21

Mar 26, 2024 07:30 AM Replimune (REPL) Appoints Sushil Patel as CEO

Mar 26, 2024 07:30 AM Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

Mar 6, 2024 08:00 AM Replimune to Present at the American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024 08:00 AM Replimune to Present at Three Upcoming Investor Conferences

Feb 15, 2024 06:40 AM Replimune Group (REPL) PT Raised to $12 at H.C. Wainwright

Feb 14, 2024 04:45 PM Form SC 13G/A Replimune Group, Inc. Filed by: Omega Fund IV, L.P.

Feb 14, 2024 04:27 PM Form SC 13G/A Replimune Group, Inc. Filed by: Redmile Group, LLC

Feb 14, 2024 10:04 AM Form SC 13G/A Replimune Group, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Feb 14, 2024 07:22 AM Form SC 13G/A Replimune Group, Inc. Filed by: Forbion Capital Fund III Cooperatief U.A.

Feb 9, 2024 12:10 PM Form SC 13G Replimune Group, Inc. Filed by: MORGAN STANLEY

Feb 8, 2024 02:46 PM Replimune Group (REPL) PT Raised to $13 at Piper Sandler

Feb 8, 2024 02:40 PM Replimune Group (REPL) PT Raised to $16 at Wedbush

Feb 8, 2024 08:10 AM Form 10-Q Replimune Group, Inc. For: Dec 31

Feb 8, 2024 08:05 AM Form 8-K Replimune Group, Inc. For: Feb 08

Feb 8, 2024 08:03 AM Replimune Group, Inc. (REPL) Tops Q3 EPS by 12c

Feb 8, 2024 08:00 AM Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Jan 26, 2024 11:52 AM Form SC 13G/A Replimune Group, Inc. Filed by: BlackRock Inc.

Jan 25, 2024 06:59 AM Form SC 13G Replimune Group, Inc. Filed by: STATE STREET CORP

Jan 16, 2024 03:59 AM DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

Jan 10, 2024 04:58 PM Form SC 13G/A Replimune Group, Inc. Filed by: BAKER BROS. ADVISORS LP

Jan 8, 2024 08:01 AM Form 8-K Replimune Group, Inc. For: Jan 08

Dec 28, 2023 08:00 AM Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 26, 2023 05:16 PM Form 8-K Replimune Group, Inc. For: Dec 26

Dec 11, 2023 06:32 AM Replimune Group (REPL) PT Lowered to $10 at H.C. Wainwright

Dec 6, 2023 06:55 AM Replimune Group (REPL) PT Lowered to $19 at JPMorgan

Dec 6, 2023 05:21 AM Replimune Group (REPL) PT Lowered to $13 at Barclays

Dec 6, 2023 04:32 AM Replimune Group (REPL) PT Lowered to $13 at BTIG

Dec 5, 2023 02:03 PM Replimune Group (REPL) PT Lowered to $14 at Wedbush

Dec 5, 2023 07:20 AM Form 8-K Replimune Group, Inc. For: Dec 05

Dec 5, 2023 07:03 AM Replimune (REPL) study of RP1 in combination with cemiplimab did not meet either of the two primary endpoints

Dec 5, 2023 07:00 AM Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed M

Dec 5, 2023 06:59 AM Replimune (REPL) Halted, News Pending

Nov 17, 2023 08:02 PM Form 4 Replimune Group, Inc. For: Nov 16 Filed by: Xynos Konstantinos